SE:ACTI Stock Latest News
Company AnnouncementsActive Biotech Clears First Safety Cohort in Tasquinimod Myelofibrosis Trial2w ago
Company AnnouncementsActive Biotech Wins Japanese Patent for Laquinimod Eye Treatment, Bolstering Global IP Strategy1M ago
Company AnnouncementsActive Biotech Deepens U.S. Ties to Advance Tasquinimod in Myelofibrosis2M ago
Company AnnouncementsActive Biotech Starts Dosing in Amended Tasquinimod Myelofibrosis Trial3M ago
Company AnnouncementsActive Biotech Updates Share Count Following Reverse Split4M ago
Company AnnouncementsActive Biotech Sets June Timetable for 1:100 Reverse Share Split5M agoCompany AnnouncementsActive Biotech AGM Backs Reverse Share Split and Expands Capital Raising Mandate5M ago
Company AnnouncementsActive Biotech Cleared to Resume Tasquinimod Myelofibrosis Trial in Europe5M ago
Company AnnouncementsActive Biotech’s LION Study Backs Laquinimod’s Potential in Posterior Eye Disease6M ago- Company AnnouncementsActive Biotech Calls 2026 AGM, Maintains Board and Withholds Dividend6M ago
Company AnnouncementsActive Biotech Wins Approval to Resume Expanded Tasquinimod Myelofibrosis Trial8M ago
Company AnnouncementsActive Biotech Updates Share Count After Completed Rights Issue9M ago
Company AnnouncementsActive Biotech Names Shareholder-Backed Nomination Committee Ahead of 2026 AGM9M ago
Company AnnouncementsActive Biotech Launches Rights Issue to Fund Key Projects11M ago
Company AnnouncementsActive Biotech’s Tasquinimod Shows Promise in Myelofibrosis Treatment11M ago- Company AnnouncementsActive Biotech Announces SEK 70 Million Rights Issue11M ago
Company AnnouncementsActive Biotech AB Approves Share Capital Amendments and Rights Issue11M ago
Company AnnouncementsActive Biotech to Present Promising Tasquinimod Data at ASH 202512M agoCompany AnnouncementsActive Biotech Announces Extraordinary General Meeting for Strategic Changes1y ago